FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3154366342> ?p ?o ?g. }

• W3154366342 endingPage "2876" @default.
• W3154366342 startingPage "2866" @default.
• W3154366342 abstract "Background and Aims: The tumor microenvironment can be divided into inflamed, immune-excluded and immune-desert phenotypes according to CD8+ T cell categories with differential programmed cell death protein 1 (PD-L1) expression. The study aims to construct a novel immunotype-based risk stratification model to predict postsurgical survival and adjuvant trans-arterial chemoembolization (TACE) response in patients with hepatocellular carcinoma (HCC). Methods: A total of 220 eligible HCC patients participated in this study. CD8 + T cell infiltration and PD-L1 expression mode were estimated by immunohistochemical staining. A risk stratification model was developed and virtualized by a nomogram that integrated these independent prognostic factors. The postoperative prognosis and adjuvant TACE benefits were evaluated with a novel immunotype-based risk stratification model. Results: A total of 220 patients were finally identified. Immune-desert, immune-excluded, and inflamed immunotypes represented 45%, 24%, and 31% of HCC, respectively. Univariate and multivariate analyses identified immunotype and PD-L1 expression mode as independent prognostic factors for overall survival time (OS) and recurrence-free survival time (RFS). The nomogram was constructed by integrating immunotype, PD-L1 expression, Barcelona Clinic Liver Cancer (BCLC) stage and tumor grade. The C-index was 0.794 in the training cohort and 0.813 in the validation cohort. A risk stratification system was constructed based on the nomogram classifying HCC patients into 3 risk groups. The average OS times in the low-risk, intermediate-risk and high-risk groups in all cohorts were 77.1 months (95% CI 71.4-82.9), 53.7 months (95% CI 48.2-59.2), and 25.6 months (95% CI 21.4-29.7), respectively. Further analysis showed that OS was significantly improved by adjuvant TACE in the low- and intermediate-risk groups (P=0.041 and P=0.010, respectively) but not in the high-risk group (P=0.398). Conclusion: A novel immunotype-based risk stratification model was built to predict postoperative prognosis and adjuvant TACE benefit in HCC patients. These tools can assist in building a more customized method of HCC treatment." @default.
• W3154366342 created "2021-04-26" @default.
• W3154366342 creator A5019023449 @default.
• W3154366342 creator A5035125189 @default.
• W3154366342 creator A5038339911 @default.
• W3154366342 creator A5052267876 @default.
• W3154366342 creator A5057973270 @default.
• W3154366342 creator A5077375928 @default.
• W3154366342 creator A5082020029 @default.
• W3154366342 date "2021-01-01" @default.
• W3154366342 modified "2023-10-01" @default.
• W3154366342 title "A Novel Immunotype-based Risk Stratification Model Predicts Postoperative Prognosis and Adjuvant TACE Benefit in Chinese Patients with Hepatocellular Carcinoma" @default.
• W3154366342 cites W1119599949 @default.
• W3154366342 cites W1516184513 @default.
• W3154366342 cites W1853436861 @default.
• W3154366342 cites W1944707476 @default.
• W3154366342 cites W1995732620 @default.
• W3154366342 cites W2013743238 @default.
• W3154366342 cites W2018786027 @default.
• W3154366342 cites W2023369016 @default.
• W3154366342 cites W2023815439 @default.
• W3154366342 cites W2026792130 @default.
• W3154366342 cites W2039123767 @default.
• W3154366342 cites W2049964698 @default.
• W3154366342 cites W2060469376 @default.
• W3154366342 cites W2074546881 @default.
• W3154366342 cites W2081871084 @default.
• W3154366342 cites W2087949560 @default.
• W3154366342 cites W2094475660 @default.
• W3154366342 cites W2098236252 @default.
• W3154366342 cites W2117920462 @default.
• W3154366342 cites W2122403898 @default.
• W3154366342 cites W2124427232 @default.
• W3154366342 cites W2128153753 @default.
• W3154366342 cites W2132478764 @default.
• W3154366342 cites W2133953792 @default.
• W3154366342 cites W2136415416 @default.
• W3154366342 cites W2151305493 @default.
• W3154366342 cites W2157058802 @default.
• W3154366342 cites W2234453634 @default.
• W3154366342 cites W2276919162 @default.
• W3154366342 cites W2277852707 @default.
• W3154366342 cites W2296767826 @default.
• W3154366342 cites W2325904644 @default.
• W3154366342 cites W2338576144 @default.
• W3154366342 cites W2402433991 @default.
• W3154366342 cites W2412696100 @default.
• W3154366342 cites W2537892258 @default.
• W3154366342 cites W2578528809 @default.
• W3154366342 cites W2592816381 @default.
• W3154366342 cites W2594491387 @default.
• W3154366342 cites W2626033245 @default.
• W3154366342 cites W2739157379 @default.
• W3154366342 cites W2761031851 @default.
• W3154366342 cites W2769528276 @default.
• W3154366342 cites W2782642721 @default.
• W3154366342 cites W2787942673 @default.
• W3154366342 cites W2794165001 @default.
• W3154366342 cites W2801494416 @default.
• W3154366342 cites W2887280975 @default.
• W3154366342 cites W2893903398 @default.
• W3154366342 cites W2917837889 @default.
• W3154366342 cites W2923934428 @default.
• W3154366342 cites W3000339487 @default.
• W3154366342 cites W3015860015 @default.
• W3154366342 cites W7614524 @default.
• W3154366342 doi "https://doi.org/10.7150/jca.54408" @default.
• W3154366342 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8040877" @default.
• W3154366342 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33854587" @default.
• W3154366342 hasPublicationYear "2021" @default.
• W3154366342 type Work @default.
• W3154366342 sameAs 3154366342 @default.
• W3154366342 citedByCount "4" @default.
• W3154366342 countsByYear W31543663422021 @default.
• W3154366342 countsByYear W31543663422022 @default.
• W3154366342 countsByYear W31543663422023 @default.
• W3154366342 crossrefType "journal-article" @default.
• W3154366342 hasAuthorship W3154366342A5019023449 @default.
• W3154366342 hasAuthorship W3154366342A5035125189 @default.
• W3154366342 hasAuthorship W3154366342A5038339911 @default.
• W3154366342 hasAuthorship W3154366342A5052267876 @default.
• W3154366342 hasAuthorship W3154366342A5057973270 @default.
• W3154366342 hasAuthorship W3154366342A5077375928 @default.
• W3154366342 hasAuthorship W3154366342A5082020029 @default.
• W3154366342 hasBestOaLocation W31543663421 @default.
• W3154366342 hasConcept C100701293 @default.
• W3154366342 hasConcept C126322002 @default.
• W3154366342 hasConcept C143998085 @default.
• W3154366342 hasConcept C192943249 @default.
• W3154366342 hasConcept C2777863537 @default.
• W3154366342 hasConcept C2778019345 @default.
• W3154366342 hasConcept C3020404979 @default.
• W3154366342 hasConcept C3527866 @default.
• W3154366342 hasConcept C502942594 @default.
• W3154366342 hasConcept C59822182 @default.
• W3154366342 hasConcept C71924100 @default.
• W3154366342 hasConcept C86803240 @default.
• W3154366342 hasConcept C88548481 @default.

• next